Research & KnowledgeEvent: September 8, 2026
Aprea Therapeutics President and CEO Oren Gilad spoke with Genetic Engineering & Biotechnology News about clinical program progress including early clinical activity with APR-1051 and expansion into additional biomarker-defined tumor populations and combination settings.
Published
Signal category
Research & Knowledge
Quote
“Oren Gilad, Ph.D., Aprea’s President and CEO, recently spoke with Genetic Engineering & Biotechnology News about the progress we’re making across our clinical programs.”
— Aprea Therapeutics team
Company
Aprea Therapeutics
Precision oncology for cancers with specific genetic alterations to potentially minimize damage to healthy cells
- Industry
- Biotechnology Research
- Location
- Doylestown, US
- Company size
- 17 employees
Aprea Therapeutics (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. We exist to ensure that cancer doesn't interrupt life's possibilities and dreams. We do this through our unique approach to synthetic lethality that is revolutionizing the future of cancer treatment.